Predicting recurrence after curative resection for gastric cancer: External validation of the Italian Research Group for Gastric Cancer (GIRCG) prognostic scoring system

Carregando...
Imagem de Miniatura
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2016
Editora
ELSEVIER SCI LTD
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
EJSO, v.42, n.1, p.123-131, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Most nomograms for Gastric Cancer (GC) were developed to predict overall survival (OS) after curative resection. The Italian Research Group for Gastric Cancer (GIRCG) prognostic scoring system (PSS) was designed to predict the recurrence risk after curative treatment based on pathologic tumor stage and treatment performed (D1 D2/D3 lymphadenectomy). This study was carried out to externally validate the GIRCG's PSS. Patients and methods: Adopting the same criteria used by GIRCG to build the PSS, 185 patients with GC operated with curative intention were selected. The median follow-up period was 77.8 months (1.93-150.8) for all patients and 102.5 months (60.9-150.8) for patients free of disease. The NRI (net reclassification improvement) was calculated to estimate the overall improvement in the reclassification of patients using the PSS in place of the TNM stage system. Results: GC recurrence occurred in 70 (37.8%) patients. The mean time to recurrence was 22.2 (range 1.9-98.1) months. For patients with recurrence, the gain in the proportion of reclassification was 0.257 (p < 0.001), indicating an improvement of 26%. For patients without recurrence, the gain in the proportion of reclassification was 0.122 (p < 0.001), indicating a worsening of 12%. The NRI calculated was 0.135 (p = 0.0527). Conclusion: The GIRCG's PSS, which predicts the likelihood of recurrence after radical surgical treatment for GC, is more accurate than TNM system to predict recurrence mainly for high-risk patients. Yet, the PSS does not have the same effectiveness for low-risk patients, overestimating the chance of recurrence occurs even for disease-free patients.
Palavras-chave
Gastric cancer, Recurrence, Lymphadenectomy, Stomach neoplasm, Gastrectomy, Adenocarcinoma, Nomogram
Referências
  1. Siewert JR, 1998, ANN SURG, V228, P449, DOI 10.1097/00000658-199810000-00002
  2. Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
  3. NAKASHIMA H, 1995, CANCER, V75, P1503, DOI 10.1002/1097-0142(19950315)75:6+<1503::AID-CNCR2820751520>3.0.CO;2-N
  4. Parkin DM, 2005, CA-CANCER J CLIN, V55, P74
  5. KORENAGA D, 1989, ARCH SURG-CHICAGO, V124, P314
  6. Bang YJ, 2010, LANCET, V376, P1302
  7. Hirabayashi S, 2014, ANN ONCOL, V25, P1179, DOI 10.1093/annonc/mdu125
  8. Marrelli D, 2005, ANN SURG, V241, P247, DOI 10.1097/01.sla.0000152019.14741.97
  9. Pedrazzani C, 2012, GASTRIC CANCER, V15, P56, DOI 10.1007/s10120-011-0063-z
  10. Marrelli D, 2012, ANN SURG, V255, P486, DOI 10.1097/SLA.0b013e3182389b1a
  11. Novotny AR, 2006, ANN SURG, V243, P74, DOI 10.1097/01.sla.0000194088.81126.85
  12. Songun I, 2010, LANCET ONCOL, V11, P439, DOI 10.1016/S1470-2045(10)70070-X
  13. SERUCA R, 1995, INT J CANCER, V64, P32, DOI 10.1002/ijc.2910640108
  14. Lee HS, 2003, J PATHOL, V200, P39, DOI 10.1002/path.1288
  15. Ribeiro U, 2006, J GASTROINTEST SURG, V10, P170, DOI 10.1016/j.gassur.2005.11.001
  16. Park CH, 2008, EJSO-EUR J SURG ONC, V34, P36, DOI 10.1016/j.ejso.2007.03.004
  17. Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908
  18. Strong VE, 2010, ANN SURG, V251, P640, DOI 10.1097/SLA.0b013e3181d3d29b
  19. Koc M, 2009, LANGENBECK ARCH SURG, V394, P755, DOI 10.1007/s00423-008-0426-z
  20. Peeters KCMJ, 2005, CANCER, V103, P702, DOI 10.1002/cncr.20783
  21. AKAMA Y, 1995, JPN J CANCER RES, V86, P617
  22. KELLER G, 1995, AM J PATHOL, V147, P593
  23. Ekstrom AM, 2000, BRIT J CANCER, V83, P391, DOI 10.1054/bjoc.2000.1205
  24. Posner M, 2006, J GASTROINTEST SURG, V10, P176
  25. Maruyama K, 1998, EUR J CANCER, V34, P1480, DOI 10.1016/S0959-8049(98)00201-9
  26. Song KY, 2014, GASTRIC CANCER, V17, P287, DOI 10.1007/s10120-013-0270-x
  27. Gold JS, 2007, ANN SURG ONCOL, V14, P3159, DOI 10.1245/s10434-007-9542-1
  28. Dikken JL, 2014, INT J RADIAT ONCOL, V88, P624, DOI 10.1016/j.ijrobp.2013.11.213
  29. Kattan MW, 2003, J CLIN ONCOL, V21, P3647, DOI 10.1200/JCO.2003.01.240
  30. Marrelli D, 2015, J AM COLL SURGEONS, V221, P280, DOI 10.1016/j.jamcollsurg.2015.03.042
  31. Miceli R, 2014, WORLD J GASTROENTERO, V20, P4516, DOI 10.3748/wjg.v20.i16.4516
  32. Marrelli D, 2015, WORLD J GASTROENTERO, V21, P7954, DOI 10.3748/wjg.v21.i26.7954
  33. Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929
  34. Han DS, 2012, J CLIN ONCOL, V30, P3834, DOI 10.1200/JCO.2012.41.8343
  35. Chen DL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076041
  36. Costa MLV, 2006, ANN SURG ONCOL, V13, P843, DOI 10.1245/ASO.2006.05.040
  37. Edge S, 2010, AJCC CANC STAGING MA
  38. Institute Nacional de Cancer Jose Alencar Gomes da Silva, 2012, INFORM VIGILANCI MAY, P1
  39. Marrelli D, 2012, SURG MULTIMODAL MANA, P35
  40. MARUYAMA K, 1987, SCAND J GASTROENTERO, V22, P63, DOI 10.3109/00365528709091021
  41. Noh SH, 2013, ANN ONCOL S4, V24, piv14, DOI [10.1093/annonc/mdt201.7, DOI 10.1093/ANNONC/MDT201.7]
  42. Paoletti X, 2010, JAMA-J AM MED ASSOC, V303, P1729, DOI 10.1001/jama.2010.534
  43. Vickers AJ, 2007, TRIALS, V5, P14
  44. Wu JH, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-40
  45. Zilberstein Bruno, 2013, Arq Bras Cir Dig, V26, P2, DOI 10.1590/S0102-67202013000100002